Recent News

• 03.04.2025 - Special Meeting of Stockholders (Virtual)
• 12.18.2024 - ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco
• 11.20.2024 - ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
• 11.14.2024 - CEO Chat
• 11.14.2024 - ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

Recent Filings

• 01.24.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 01.17.2025 - DEF 14A Other definitive proxy statements
• 12.30.2024 - 424B3 Prospectus [Rule 424(b)(3)]
• 12.26.2024 - EFFECT Notice of Effectiveness
• 12.26.2024 - CORRESP Correspondence
• 12.23.2024 - UPLOAD SEC-generated letter
• 12.20.2024 - S-3 Registration statement under Securities Act of 1933
• 12.20.2024 - PRE 14A Other preliminary proxy statements
• 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2024 - 8-K Current report